5 articles
Anaplastic large-cell lymphoma
Anaplastic large-cell lymphoma (ALCL) is an aggressive CD30-positive T-cell non-Hodgkin lymphoma, divided by the WHO into primary cutaneous, ALK-positive, and ALK-negative entities with differing genetics and survival.
Anaplastic lymphoma kinase
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase gene on 2p23, first cloned in 1994 via the NPM-ALK fusion in lymphoma; EML4-ALK rearrangements drive non-small cell lung cancer and are treated with crizotinib through lorlatinib.
Breast implant-associated anaplastic large cell lymphoma
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), also called seroma-associated ALCL, is a rare CD30-positive, ALK-negative T-cell non-Hodgkin lymphoma arising in the capsule around textured breast implants, typically 7-10 years after placement, treated by en bloc resection.
Hydroa vacciniforme-like lymphoma
Hydroa vacciniforme-like lymphoma (HVLL), now hydroa vacciniforme lymphoproliferative disorder, is a rare EBV-positive T/NK-cell lymphoproliferative disease of childhood, mainly in Asia and Latin America, with ulcerative skin lesions and risk of systemic lymphoma.
Karpas-299
Karpas-299 (K299, CVCL_1324) is a human CD30+ ALK-positive anaplastic large cell lymphoma cell line established in 1986 from a 25-year-old man's blood, carrying the NPM-ALK fusion from t(2;5), used widely in ALK inhibitor resistance research.